Ocugen, Inc. SEC filings OCGN
Ocugen, Inc. has 892 filings in SEC EDGAR's recent list, going back to Aug 7, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Aug 14, 2026 | — |
| DEFA14A | Additional proxy material | Jul 30, 2026 | — |
| DEF 14A | Proxy statement | Jul 30, 2026 | Sep 21, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 20, 2026 | Sep 21, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 11, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | Jun 18, 2024 | — |
| DEF 14A | Proxy statement | May 28, 2024 | Jun 28, 2024 |
| PRE 14A | Preliminary proxy statement | May 17, 2024 | Jun 28, 2024 |
| DEFA14A | Additional proxy material | Jun 21, 2023 | — |
| DEFA14A | Additional proxy material | Jun 20, 2023 | — |
| DEFA14A | Additional proxy material | Jun 9, 2023 | — |
| DEFA14A | Additional proxy material | May 30, 2023 | — |
| DEFA14A | Additional proxy material | May 24, 2023 | — |
| DEFA14A | Additional proxy material | May 22, 2023 | — |
| DEFA14A | Additional proxy material | May 17, 2023 | — |
| DEFA14A | Additional proxy material | May 15, 2023 | — |
| DEFA14A | Additional proxy material | May 11, 2023 | — |
| DEFA14A | Additional proxy material | May 8, 2023 | — |
| DEF 14A | Proxy statement | Apr 20, 2023 | Jun 9, 2023 |
| DEFA14A | Additional proxy material | Jun 1, 2022 | — |
| DEFA14A | Additional proxy material | May 26, 2022 | — |
| DEFA14A | Additional proxy material | May 24, 2022 | — |
| DEFA14A | Additional proxy material | May 20, 2022 | — |
| DEFA14A | Additional proxy material | May 18, 2022 | — |
| DEFA14A | Additional proxy material | May 13, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Jun 25, 2021 | — |
| DEFA14A | Additional proxy material | Jun 22, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2021 | Jun 11, 2021 |
| DEFA14A | Additional proxy material | Feb 22, 2021 | — |
| DEF 14A | Proxy statement | Feb 22, 2021 | Mar 16, 2021 |
| PRE 14A | Preliminary proxy statement | Feb 11, 2021 | Mar 16, 2021 |
| DEFA14A | Additional proxy material | Jan 12, 2021 | — |
| DEFA14A | Additional proxy material | Dec 23, 2020 | — |
| DEFA14A | Additional proxy material | Dec 11, 2020 | — |
| DEFA14A | Additional proxy material | Dec 2, 2020 | — |
| DEF 14A | Proxy statement | Oct 30, 2020 | Dec 11, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 20, 2020 | Oct 20, 2020 |
| DEF 14A | Proxy statement | Nov 8, 2019 | Dec 18, 2019 |
| PRE 14A | Preliminary proxy statement | Oct 18, 2018 | Oct 18, 2018 |
| DEFA14A | Additional proxy material | Apr 26, 2018 | — |
| DEF 14A | Proxy statement | Apr 26, 2018 | Jun 15, 2018 |
| DEFA14A | Additional proxy material | Apr 27, 2017 | — |
| DEF 14A | Proxy statement | Apr 27, 2017 | Jun 13, 2017 |
| DEF 14A | Proxy statement | Nov 2, 2016 | Nov 22, 2016 |
| PRE 14A | Preliminary proxy statement | Oct 3, 2016 | Oct 3, 2016 |
| DEFA14A | Additional proxy material | May 4, 2016 | — |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 22, 2016 |
| DEFA14A | Additional proxy material | Apr 28, 2015 | — |
| DEF 14A | Proxy statement | Apr 28, 2015 | Jun 24, 2015 |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OCGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1372299
- Former names
- HISTOGENICS CORP (until Sep 26, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.